The content on this site is intended for healthcare professionals only
Prof Hesham El-Ghazaly speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the combination of chemotherapy and hormone therapy for the treatment of luminal metastatic breast cancer.
He states that this combination has improved the progression-free survival in both the adjuvant and metastatic setting.
Prof El-Ghazaly mentions a phase III trial comparing the use of an aromatase inhibitor alone versus an aromatase inhibitor plus capecitabine, which has generated promising results so far.
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
OncoAlert round up July 28th to August 3rd, 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Loco-regional management after neoadjuvant chemotherapy
